Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer.

Wang T, Narayanaswamy R, Ren H, Gillespie JW, Petrenko VA, Torchilin VP.

J Drug Target. 2018 Jun - Jul;26(5-6):505-515. doi: 10.1080/1061186X.2017.1405424. Epub 2017 Dec 1.

PMID:
29132246
2.

Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.

Petrenko VA, Gillespie JW.

Expert Opin Drug Deliv. 2017 Mar;14(3):373-384. doi: 10.1080/17425247.2016.1218463. Epub 2016 Aug 5. Review.

3.

Selection of Lung Cancer-Specific Landscape Phage for Targeted Drug Delivery.

Gillespie JW, Wei L, Petrenko VA.

Comb Chem High Throughput Screen. 2016;19(5):412-22.

4.

Promiscuous tumor targeting phage proteins.

Gross AL, Gillespie JW, Petrenko VA.

Protein Eng Des Sel. 2016 Mar;29(3):93-103. doi: 10.1093/protein/gzv064. Epub 2016 Jan 12.

5.

An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers.

Prueitt RL, Wallace TA, Glynn SA, Yi M, Tang W, Luo J, Dorsey TH, Stagliano KE, Gillespie JW, Hudson RS, Terunuma A, Shoe JL, Haines DC, Yfantis HG, Han M, Martin DN, Jordan SV, Borin JF, Naslund MJ, Alexander RB, Stephens RM, Loffredo CA, Lee DH, Putluri N, Sreekumar A, Hurwitz AA, Ambs S.

Cancer Res. 2016 Mar 1;76(5):1055-1065. doi: 10.1158/0008-5472.CAN-14-3630. Epub 2015 Dec 30.

6.

Tailoring Interfacial Properties by Controlling Carbon Nanotube Coating Thickness on Glass Fibers Using Electrophoretic Deposition.

Tamrakar S, An Q, Thostenson ET, Rider AN, Haque BZ, Gillespie JW Jr.

ACS Appl Mater Interfaces. 2016 Jan 20;8(2):1501-10. doi: 10.1021/acsami.5b10903. Epub 2016 Jan 5.

PMID:
26699906
7.

Abdominal Wall Reconstruction for Large Ventral Hernias in the Octogenarian.

Gillespie JW 3rd, Zabel DD, Conway MK, Kalish ED, Sarmiento Garzon DE.

Am Surg. 2015 Nov;81(11):E373-5. No abstract available.

PMID:
26672570
8.

Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins.

Gillespie JW, Gross AL, Puzyrev AT, Bedi D, Petrenko VA.

Front Microbiol. 2015 Jun 23;6:628. doi: 10.3389/fmicb.2015.00628. eCollection 2015.

9.

Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors.

Wang T, Yang S, Mei LA, Parmar CK, Gillespie JW, Praveen KP, Petrenko VA, Torchilin VP.

Mol Cancer Ther. 2014 Dec;13(12):2864-75. doi: 10.1158/1535-7163.MCT-14-0052. Epub 2014 Sep 19. Erratum in: Mol Cancer Ther. 2015 Jun;14(6):1517.

10.

Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.

Bedi D, Gillespie JW, Petrenko VA.

Protein Eng Des Sel. 2014 Jul;27(7):235-43. doi: 10.1093/protein/gzu020. Epub 2014 Jun 4.

11.

Split hemianterior tibialis turndown muscle flap for coverage of distal leg wounds with preservation of function.

Gundlapalli V, Gillespie JW 3rd, Tzarnas CD.

Eplasty. 2014 Mar 21;14:e12. eCollection 2014.

12.

Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.

Wang T, Hartner WC, Gillespie JW, Praveen KP, Yang S, Mei LA, Petrenko VA, Torchilin VP.

Nanomedicine. 2014 Feb;10(2):421-30. doi: 10.1016/j.nano.2013.08.009. Epub 2013 Sep 9.

13.

Effects of interaction volume on X-ray line-scans across an ultrasonically consolidated aluminum/copper interface.

Mueller JE, Gillespie JW Jr, Advani SG.

Scanning. 2013 Sep-Oct;35(5):327-35. doi: 10.1002/sca.21071. Epub 2012 Dec 17.

PMID:
23254952
14.

Targeted delivery of siRNA into breast cancer cells via phage fusion proteins.

Bedi D, Gillespie JW, Petrenko VA Jr, Ebner A, Leitner M, Hinterdorfer P, Petrenko VA.

Mol Pharm. 2013 Feb 4;10(2):551-9. doi: 10.1021/mp3006006. Epub 2013 Jan 8.

15.

Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer.

Gannot G, Richardson AM, Rodriguez-Canales J, Pinto PA, Merino MJ, Chuaqui RF, Gillespie JW, Emmert-Buck MR.

Am J Cancer Res. 2011;1(1):120-127. Epub 2010 Nov 10.

16.

Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes.

Bedi D, Musacchio T, Fagbohun OA, Gillespie JW, Deinnocentes P, Bird RC, Bookbinder L, Torchilin VP, Petrenko VA.

Nanomedicine. 2011 Jun;7(3):315-23. doi: 10.1016/j.nano.2010.10.004. Epub 2010 Nov 2.

17.

Influence of hypoxia induced by minimally invasive prostatectomy on gene expression: implications for biomarker analysis.

Erickson HS, Josephson JW, Vira M, Albert PS, Gillespie JW, Rodriguez-Canales J, Pinto PA, Chuaqui RF, Emmert-Buck MR, Coleman JA.

Am J Transl Res. 2010 Apr 10;2(3):210-22.

18.

Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.

Jayanna PK, Bedi D, Gillespie JW, DeInnocentes P, Wang T, Torchilin VP, Bird RC, Petrenko VA.

Nanomedicine. 2010 Aug;6(4):538-46. doi: 10.1016/j.nano.2010.01.005. Epub 2010 Feb 4.

19.

High throughput screening of normal and neoplastic tissue samples.

Erickson HS, Gannot G, Tangrea MA, Chuaqui RF, Gillespie JW, Emmert-Buck MR.

Comb Chem High Throughput Screen. 2010 Mar;13(3):253-67. Review.

PMID:
20015016
20.

The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.

Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, Singh SP, Bedolla RB, Peled A, Troyer DA, Pikarsky E, Karin M, Farber JM.

PLoS One. 2009 Aug 19;4(8):e6695. doi: 10.1371/journal.pone.0006695.

21.

Quantitative RT-PCR gene expression analysis of laser microdissected tissue samples.

Erickson HS, Albert PS, Gillespie JW, Rodriguez-Canales J, Marston Linehan W, Pinto PA, Chuaqui RF, Emmert-Buck MR.

Nat Protoc. 2009;4(6):902-22. doi: 10.1038/nprot.2009.61. Epub 2009 May 21.

22.

Tissue microdissection.

Erickson HS, Gillespie JW, Emmert-Buck MR.

Methods Mol Biol. 2008;424:433-48. doi: 10.1007/978-1-60327-064-9_34. Review.

PMID:
18369881
23.

Tumor immunobiological differences in prostate cancer between African-American and European-American men.

Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S.

Cancer Res. 2008 Feb 1;68(3):927-36. doi: 10.1158/0008-5472.CAN-07-2608.

24.

Assessment of normalization strategies for quantitative RT-PCR using microdissected tissue samples.

Erickson HS, Albert PS, Gillespie JW, Wallis BS, Rodriguez-Canales J, Linehan WM, Gonzalez S, Velasco A, Chuaqui RF, Emmert-Buck MR.

Lab Invest. 2007 Sep;87(9):951-62. Epub 2007 Jul 23.

25.

Layered peptide array for multiplex immunohistochemistry.

Gannot G, Tangrea MA, Erickson HS, Pinto PA, Hewitt SM, Chuaqui RF, Gillespie JW, Emmert-Buck MR.

J Mol Diagn. 2007 Jul;9(3):297-304.

26.

Continuous silica coatings on glass fibers via bioinspired approaches.

Pogula SD, Patwardhan SV, Perry CC, Gillespie JW Jr, Yarlagadda S, Kiick KL.

Langmuir. 2007 Jun 5;23(12):6677-83. Epub 2007 May 10.

PMID:
17489615
27.

Layered peptide arrays: a diverse technique for antibody screening of clinical samples.

Gannot G, Tangrea MA, Chuaqui RF, Gillespie JW, Emmert-Buck MR.

Ann N Y Acad Sci. 2007 Mar;1098:451-3.

PMID:
17435150
28.

Identification of a unique epigenetic sub-microenvironment in prostate cancer.

Rodriguez-Canales J, Hanson JC, Tangrea MA, Erickson HS, Albert PS, Wallis BS, Richardson AM, Pinto PA, Linehan WM, Gillespie JW, Merino MJ, Libutti SK, Woodson KG, Emmert-Buck MR, Chuaqui RF.

J Pathol. 2007 Mar;211(4):410-9.

PMID:
17278115
29.

Prostate cancer epigenetics: a review on gene regulation.

Diaw L, Woodson K, Gillespie JW.

Gene Regul Syst Bio. 2007 Dec 11;1:313-25.

30.

Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer.

Grover AC, Tangrea MA, Woodson KG, Wallis BS, Hanson JC, Chuaqui RF, Gillespie JW, Erickson HS, Bonner RF, Pohida TJ, Emmert-Buck MR, Libutti SK.

J Transl Med. 2006 Mar 2;4:13.

31.

Gene promoter methylation in prostate tumor-associated stromal cells.

Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG.

J Natl Cancer Inst. 2006 Feb 15;98(4):255-61.

PMID:
16478744
32.

Layered peptide arrays: high-throughput antibody screening of clinical samples.

Gannot G, Tangrea MA, Gillespie JW, Erickson HS, Wallis BS, Leakan RA, Knezevic V, Hartmann DP, Chuaqui RF, Emmert-Buck MR.

J Mol Diagn. 2005 Oct;7(4):427-36.

33.

Molecular alterations in primary prostate cancer after androgen ablation therapy.

Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6823-34.

34.

Novel proteomic approaches for tissue analysis.

Tangrea MA, Wallis BS, Gillespie JW, Gannot G, Emmert-Buck MR, Chuaqui RF.

Expert Rev Proteomics. 2004 Aug;1(2):185-92. Review.

PMID:
15966813
35.

Optimal molecular profiling of tissue and tissue components: defining the best processing and microdissection methods for biomedical applications.

Bova GS, Eltoum IA, Kiernan JA, Siegal GP, Frost AR, Best CJ, Gillespie JW, Su GH, Emmert-Buck MR.

Mol Biotechnol. 2005 Feb;29(2):119-52. Review.

PMID:
15699569
36.

Histomathematical analysis of clinical specimens: challenges and progress.

Gannot G, Gillespie JW, Chuaqui RF, Tangrea MA, Linehan WM, Emmert-Buck MR.

J Histochem Cytochem. 2005 Feb;53(2):177-85.

PMID:
15684330
37.

Optimal molecular profiling of tissue and tissue components: defining the best processing and microdissection methods for biomedical applications.

Bova GS, Eltoum IA, Kiernan JA, Siegal GP, Frost AR, Best CJ, Gillespie JW, Emmert-Buck MR.

Methods Mol Med. 2005;103:15-66. Review.

PMID:
15542897
38.

Expression microdissection: operator-independent retrieval of cells for molecular profiling.

Tangrea MA, Chuaqui RF, Gillespie JW, Ahram M, Gannot G, Wallis BS, Best CJ, Linehan WM, Liotta LA, Pohida TJ, Bonner RF, Emmert-Buck MR.

Diagn Mol Pathol. 2004 Dec;13(4):207-12.

PMID:
15538110
39.

Comparison of snap freezing versus ethanol fixation for gene expression profiling of tissue specimens.

Perlmutter MA, Best CJ, Gillespie JW, Gathright Y, González S, Velasco A, Linehan WM, Emmert-Buck MR, Chuaqui RF.

J Mol Diagn. 2004 Nov;6(4):371-7.

40.

Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays.

Sriuranpong V, Mutirangura A, Gillespie JW, Patel V, Amornphimoltham P, Molinolo AA, Kerekhanjanarong V, Supanakorn S, Supiyaphun P, Rangdaeng S, Voravud N, Gutkind JS.

Clin Cancer Res. 2004 Aug 1;10(15):4944-58.

41.

Molecular profiling of cancer.

Gillespie JW, Gannot G, Tangrea MA, Ahram M, Best CJ, Bichsel VE, Petricoin EF, Emmert-Buck MR, Chuaqui RF.

Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:67-71. Review.

PMID:
15209405
42.

Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer.

Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF 3rd.

Proteomics. 2003 Sep;3(9):1801-10.

PMID:
12973739
43.

Handling of clinical tissue specimens for molecular profiling studies.

Leiva IM, Emmert-Buck MR, Gillespie JW.

Curr Issues Mol Biol. 2003 Apr;5(2):27-35. Review.

44.

Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis.

Best CJ, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, Bostwick DG, Linehan WM, Emmert-Buck MR.

Diagn Mol Pathol. 2003 Jun;12(2):63-70.

PMID:
12766610
45.

Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications.

Ahram M, Flaig MJ, Gillespie JW, Duray PH, Linehan WM, Ornstein DK, Niu S, Zhao Y, Petricoin EF 3rd, Emmert-Buck MR.

Proteomics. 2003 Apr;3(4):413-21.

PMID:
12687609
46.

Preneoplastic lesions of the prostate-clinical, pathological and molecular biological aspects.

Nasir A, Copeland J, Gillespie JW, Chughtai OR, Andrawis R, Kaiser HE, Manyak MJ.

In Vivo. 2002 Nov-Dec;16(6):557-66. Review.

PMID:
12494901
47.

Post-analysis follow-up and validation of microarray experiments.

Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR.

Nat Genet. 2002 Dec;32 Suppl:509-14. Review.

PMID:
12454646
48.

2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers.

Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF 3rd, Zhao Y.

Mol Cell Proteomics. 2002 Feb;1(2):117-24.

49.

The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells.

Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD, Rhim JS, Emmert-Buck MR, Linehan WM, Lerman MI.

Cancer Res. 2002 Jun 15;62(12):3498-502.

50.

Evaluation of non-formalin tissue fixation for molecular profiling studies.

Gillespie JW, Best CJ, Bichsel VE, Cole KA, Greenhut SF, Hewitt SM, Ahram M, Gathright YB, Merino MJ, Strausberg RL, Epstein JI, Hamilton SR, Gannot G, Baibakova GV, Calvert VS, Flaig MJ, Chuaqui RF, Herring JC, Pfeifer J, Petricoin EF, Linehan WM, Duray PH, Bova GS, Emmert-Buck MR.

Am J Pathol. 2002 Feb;160(2):449-57.

Supplemental Content

Loading ...
Support Center